Based on the FIGHT-202 trial, the United States Food and Drug Administration (FDA) granted an accelerated approval for previously treated unresectable locally advanced CCA with FGFR2 fusion or other rearrangements [86]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.